These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 21351854)

  • 1. Pharmacoeconomics of darunavir.
    Fullerton DS; Smets E; De La Rosa G; Mrus JM
    Expert Rev Pharmacoecon Outcomes Res; 2011 Feb; 11(1):27-39. PubMed ID: 21351854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-minimization comparison of darunavir plus ritonavir and lopinavir/ritonavir in HIV-1 infected treatment-naïve women of childbearing age.
    Möller J; Desai K; Simpson K; Baran RW; Van de Steen O; Dietz B; Gooch K
    J Med Econ; 2014 Apr; 17(4):250-8. PubMed ID: 24351091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.
    Brogan A; Mauskopf J; Talbird SE; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():129-46. PubMed ID: 21182348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of economic evaluations of darunavir boosted by low-dose ritonavir in treatment-experienced persons living with HIV infection.
    Mauskopf J; Annemans L; Hill AM; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():1-16. PubMed ID: 21182340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.
    Moeremans K; Hemmett L; Hjelmgren J; Allegri G; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():147-67. PubMed ID: 21182349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.
    Mauskopf J; Brogan A; Martin S; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():83-105. PubMed ID: 21182346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.
    Moeremans K; Annemans L; Löthgren M; Allegri G; Wyffels V; Hemmet L; Caekelbergh K; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():107-28. PubMed ID: 21182347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States.
    Brogan AJ; Mrus J; Hill A; Sawyer AW; Smets E
    HIV Clin Trials; 2010; 11(3):133-44. PubMed ID: 20736150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: the POWER experience.
    Hill AM; Clotet B; Johnson M; Stoll M; Bellos N; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():69-81. PubMed ID: 21182345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of costs by CD4 count category for the darunavir/r 600/100 mg bid and control protease inhibitor arms of the POWER 1 and 2 trials.
    Hill A; Hemmett L; Wilson B
    HIV Clin Trials; 2007; 8(5):303-10. PubMed ID: 17956831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting direct costs of HIV care during the first year of darunavir-based highly active antiretroviral therapy using CD4 cell counts: evidence from POWER.
    Hill AM; Gebo K; Hemmett L; Löthgren M; Allegri G; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():169-81. PubMed ID: 21182350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Budget impact analysis of switching to darunavir/ritonavir monotherapy for HIV-infected people in Spain.
    Pasquau J; Gostkorzewicz J; Ledesma F; Anceau A; Hill A; Moecklinghoff C
    Appl Health Econ Health Policy; 2012 Mar; 10(2):139-41. PubMed ID: 22293019
    [No Abstract]   [Full Text] [Related]  

  • 13. Predicting HIV care costs using CD4 counts from clinical trials.
    Hill A; Gebo K
    Am J Manag Care; 2007 Sep; 13(9):524-8. PubMed ID: 17803366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
    Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L
    AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Darunavir: a nonpeptidic antiretroviral protease inhibitor.
    McCoy C
    Clin Ther; 2007 Aug; 29(8):1559-76. PubMed ID: 17919539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.
    De Meyer S; Lathouwers E; Dierynck I; De Paepe E; Van Baelen B; Vangeneugden T; Spinosa-Guzman S; Lefebvre E; Picchio G; de Béthune MP
    AIDS; 2009 Sep; 23(14):1829-40. PubMed ID: 19474650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients.
    Cahn P; Fourie J; Grinsztejn B; Hodder S; Molina JM; Ruxrungtham K; Workman C; Van De Casteele T; De Doncker P; Lathouwers E; Tomaka F
    AIDS; 2011 Apr; 25(7):929-39. PubMed ID: 21346512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy.
    Pulido F; Arribas JR; Hill A; Van Delft Y; Moecklinghoff C
    Antivir Ther; 2011; 16(1):59-65. PubMed ID: 21311109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents.
    Blanche S; Bologna R; Cahn P; Rugina S; Flynn P; Fortuny C; Vis P; Sekar V; van Baelen B; Dierynck I; Spinosa-Guzman S
    AIDS; 2009 Sep; 23(15):2005-13. PubMed ID: 19724191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic interactions between ritonavir-boosted darunavir and NNRTIs: a report of 3 cases.
    Rawizza HE; Sax PE
    AIDS Read; 2008 Sep; 18(9):466-72, 478-9. PubMed ID: 18828231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.